Endocrinology Advisor

Faricimab Upholds, Improves Visual Acuity With Fewer Injections in DME

In diabetic macular edema, faricimab can improve visual acuity for treatment-naïve eyes or sustain vision for those ...
PharmiWeb

Ophthalmology Drugs Market Analysis by Key Drivers, Top Players, Forecast, Growth Rate, Constraints, Future Trends, Events, And Challenges Until 2030

Global Ophthalmology Drugs Market OutlookThe global ophthalmology drugs market is forecasted to expand at a CAGR of nearly 8% over the next several years, driven by the rising burden of vision ...
Center for Biosimilars

Biosimilar QL1207 Demonstrates Equivalent Efficacy and Safety in DME

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
Ophthalmology Times

Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD

Ocular Therapeutix announced it plans to accelerate its intended New Drug Application (NDA) for AXPAXLI (OTX-TKI) for the ...
Ophthalmology Advisor

Anti-VEGF Reduces Myopia Odds in ROP, But Comes With Higher Risks

Anti-VEGF therapy for patients with retinopathy of prematurity reduces myopia compared with laser treatments, but comes with other risks.